CLN8

Across TCGA pan-cancer cohorts, CLN8 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CLN8 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CLN8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLN8 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where CLN8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.349	0.988	.006	18	view →
LSCC	DFS	Quartile	All	0.568	0.935	.008	17	view →
CCRCC	DFS	Median	All	0.958	0.583	.002	13	view →
LUAD	DFS	Median	All	1.000	0.675	.034	4	view →
GBM	OS	Quartile	All	0.852	0.378	.032	1	view →
HNSC	OS	Tertile	IV	0.893	0.655	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CLN8–PDAC (DFS)

Open the PDAC breakdown →